Ligand Pharmaceuticals LGND Primrose mRNA — Financial Royalty Assets, Allowance

Other product segments

Qarziba

$480K—

Similar metrics at other companies

NOVRoyalty — Contract With Customer Receivable Allowance For Credit Loss

$78M+144%

NOVRoyalty — Contract With Customer Receivable After Allowance For Credit Loss

$43M+231%

BPOPPR — Financing Receivable Nonaccrual With Allowance

$318.57M+88.5%

BPOPPR — Financing Receivable Nonaccrual No Allowance

$101.7M+9.4%

BBIODeferred royalty obligations, net

$871.19M+75.2%

SCIValuation Allowances And Reserves Balance

$108.83M-8.5%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's primrose mrna — financial royalty assets, allowance.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's primrose mrna — financial royalty assets, allowance?: Ligand Pharmaceuticals (LGND) reported primrose mrna — financial royalty assets, allowance of $98K in Q1 2026.
What does primrose mrna — financial royalty assets, allowance mean?: Reflects the cumulative valuation adjustment or reserve established against the gross carrying value of royalty assets in the mRNA segment. This allowance accounts for expected credit losses or potential uncollectibility of future royalty streams. It is a critical indicator of management's assessment of the credit risk and recoverability of the segment's royalty-based assets.